Chemistry:BMS-955176
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C42H62N2O4S |
| Molar mass | 691.03 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]
Studies
Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]
It appears that development of BMS-955176 has been terminated.[6]
See also
References
- ↑ "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml.
- ↑ "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform". http://www.projectinform.org/hiv-news/croi2015-new-hiv-maturation-inhibitor-bms-955176-appears-more-potent-than-earlier-beviramat/.
- ↑ "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B 5 (6): 493–9. November 2015. doi:10.1016/j.apsb.2015.05.004. PMID 26713265.
- ↑ 4.0 4.1 "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor.
- ↑ "HIV maturation inhibitor BMS-955176 looks promising in early study". http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/.
- ↑ "GSK Discontinues Development of Maturation Inhibitor BMS-955176". http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html.
 |  |
